Article Details
Retrieved on: 2021-12-03 21:36:44
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The Alexion deal granted AstraZeneca the rights to Alexion's complement inhibitors Soliris and Ultomiris plus a clutch of other assets. Read more on.
Article found on: www.fiercepharma.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here